Vanguard Personalized Indexing Management LLC Buys 1,052 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Vanguard Personalized Indexing Management LLC lifted its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 20.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,312 shares of the biopharmaceutical company’s stock after buying an additional 1,052 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Intra-Cellular Therapies were worth $432,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Amalgamated Bank lifted its position in Intra-Cellular Therapies by 117.3% in the second quarter. Amalgamated Bank now owns 6,922 shares of the biopharmaceutical company’s stock worth $474,000 after purchasing an additional 3,736 shares during the period. Virtu Financial LLC acquired a new position in shares of Intra-Cellular Therapies in the 2nd quarter valued at $1,420,000. Renaissance Technologies LLC lifted its holdings in shares of Intra-Cellular Therapies by 130.0% during the 2nd quarter. Renaissance Technologies LLC now owns 222,400 shares of the biopharmaceutical company’s stock worth $15,232,000 after acquiring an additional 125,700 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of Intra-Cellular Therapies by 21.9% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 35,492 shares of the biopharmaceutical company’s stock valued at $2,431,000 after acquiring an additional 6,382 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale increased its stake in Intra-Cellular Therapies by 1.0% in the second quarter. DekaBank Deutsche Girozentrale now owns 52,499 shares of the biopharmaceutical company’s stock valued at $3,714,000 after acquiring an additional 502 shares during the period. 92.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. The Goldman Sachs Group decreased their price objective on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reiterated a “buy” rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $130.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Canaccord Genuity Group upped their target price on shares of Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a “buy” rating in a research report on Thursday, June 20th. Finally, UBS Group decreased their price target on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $96.58.

Insider Activity

In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the transaction, the executive vice president now directly owns 29,700 shares in the company, valued at $2,229,876. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Sharon Mates sold 28,680 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $74.46, for a total transaction of $2,135,512.80. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $79,696,697.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mark Neumann sold 18,714 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the completion of the sale, the executive vice president now directly owns 29,700 shares in the company, valued at $2,229,876. The disclosure for this sale can be found here. Insiders sold 175,316 shares of company stock valued at $13,037,345 in the last quarter. Company insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Stock Performance

Shares of Intra-Cellular Therapies stock opened at $73.30 on Friday. The firm has a fifty day moving average of $75.47 and a two-hundred day moving average of $71.66. The stock has a market capitalization of $7.74 billion, a price-to-earnings ratio of -63.19 and a beta of 1.00. Intra-Cellular Therapies, Inc. has a 52 week low of $45.50 and a 52 week high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.03. Intra-Cellular Therapies had a negative net margin of 14.93% and a negative return on equity of 11.48%. The business had revenue of $161.40 million for the quarter, compared to analyst estimates of $157.74 million. During the same quarter last year, the firm earned ($0.45) EPS. Intra-Cellular Therapies’s quarterly revenue was up 45.7% compared to the same quarter last year. As a group, research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current fiscal year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.